Review
Medicine, General & Internal
Marina Magrey, Sergio Schwartzman, Natasha de Peyrecave, Victor S. Sloan, Jeffrey L. Stark
Summary: Nonradiographic axial spondyloarthritis (nr-axSpA) is a distinct phenotype within the spectrum of axial spondyloarthritis, with comparable clinical manifestations and disease burden to ankylosing spondylitis. However, there is a need for improved recognition and management of nr-axSpA.
Review
Orthopedics
Philip Mease, Atul Deodhar
Summary: Accurate diagnosis of nonradiographic axial spondyloarthritis is crucial for optimal treatment.
BMC MUSCULOSKELETAL DISORDERS
(2022)
Article
Rheumatology
Hyemin Jeong, Yong-Gil Kim, Tae-Hwan Kim, Tae-Jong Kim, Min-Chan Park, Mi Ryoung Seo, Kichul Shin, Ji Seon Oh, Sang-Hoon Lee, Yeon-Ah Lee, Eun Young Lee, Han Joo Baek, Hoon-Suk Cha
Summary: This study evaluated the clinical characteristics and natural history of non-radiographic axial spondyloarthritis (nr-axSpA) using KONASPA data from South Korea. Results showed that female patients with nr-axSpA had a later disease onset and more extra-articular manifestations compared to male patients. Risk factors for progression to ankylosing spondylitis included young age at symptom onset, high BMI, and presence of radiographic sacroiliitis at diagnosis.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
(2021)
Article
Rheumatology
Victoria Navarro-Compan, Diego Benavent, Dafne Capelusnik, Desiree van der Heijde, Robert B. M. Landewe, Denis Poddubnyy, Astrid van Tubergen, Xenofon Baraliakos, Filip E. van den Bosch, Floris A. van Gaalen, Lianne Gensler, Clementina Lopez-Medina, Helena Marzo-Ortega, Anna Molto, Rodolfo Perez-Alamino, Martin Rudwaleit, Marleen van de Sande, Raj Sengupta, Ulrich Weber, Sofia Ramiro
Summary: This study developed a consensual definition for 'early axial spondyloarthritis-axSpA' and 'early peripheral spondyloarthritis-pSpA' through a systematic literature review and Delphi survey. The results indicated that early axSpA should be based on symptom duration only, without considering the presence of radiographic damage.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Medicine, Research & Experimental
Xavier Juanola, Manuel J. Moreno Ramos, Joaquin Maria Belzunegui, Cristina Fernandez-Carballido, Jordi Gratacos
Summary: Axial spondyloarthritis is a chronic inflammatory rheumatic disease that affects the axial skeleton and causes severe pain and disability. Early diagnosis and appropriate treatment can reduce the severity of the disease and the risk of progression. Different types of drugs, such as bDMARDs and JAK inhibitors, are available for treatment. However, treatment failure is common and requires individualized treatment strategies.
ADVANCES IN THERAPY
(2022)
Article
Rheumatology
Tamara Rusman, Mignon A. C. van der Weijden, Michael T. Nurmohamed, Robert B. M. Landewe, Janneke J. H. de Winter, Bouke J. H. Boden, Pierre M. Bet, Carmella M. A. van der Bijl, Conny van der Laken, Irene E. Van der Horst-Bruinsma
Summary: The study investigated the efficacy of 16-week treatment with etanercept in patients with suspected nonradiographic axial SpA. Results showed that etanercept treatment was not effective in patients with high disease activity but without positive findings on SI joint MRI and/or elevated CRP level.
ARTHRITIS & RHEUMATOLOGY
(2021)
Article
Rheumatology
Tamara Rusman, Mignon A. C. van der Weijden, Michael T. Nurmohamed, Robert B. M. Landewe, Janneke J. H. de Winter, Bouke J. H. Boden, Pierre M. Bet, Carmella M. A. van der Bijl, Conny van der Laken, Irene E. van der Horst-Bruinsma
Summary: This study demonstrates that treatment with etanercept is not effective in patients with suspected nonradiographic axial spondyloarthritis with high disease activity but without the requirement of a positive finding on SI joint MRI and/or elevated CRP level.
ARTHRITIS & RHEUMATOLOGY
(2021)
Article
Rheumatology
Filip Van den Bosch, James Cheng-Chung Wei, Peter Nash, Francisco J. Blanco, Daniela Graham, Chuanbo Zang, Edmund Arthur, Cecilia Borlenghi, Vassilis Tsekouras, Bonnie Vlahos, Atul Deodhar
Summary: This study investigated the withdrawal and retreatment of etanercept in patients with nr-axSpA achieving inactive disease. The results showed that approximately 25% of patients maintained inactive disease for 40 weeks after discontinuing etanercept. Baseline absence of MRI sacroiliitis and high hs-CRP predicted response maintenance after etanercept withdrawal.
JOURNAL OF RHEUMATOLOGY
(2023)
Review
Rheumatology
Rainer Hintenberger, Barbara Affenzeller, Valeriia Vladychuk, Herwig Pieringer
Summary: Cardiovascular manifestations are frequently observed in patients with axial spondyloarthritis, leading to significant morbidity and disease burden. We conducted a thorough review of articles published between January 2000 and May 25, 2023, focusing on cardiovascular manifestations in axial spondyloarthritis. Despite a lack of research on non-radiographic axial spondyloarthritis, evidence suggests a strong association between traditional risk factors and increased cardiovascular disease burden or major cardiovascular events in patients with spondyloarthropathies. Considering disease activity as a major determinant of morbidity, diagnostic, therapeutic, and lifestyle interventions are crucial for improving outcomes.
CLINICAL RHEUMATOLOGY
(2023)
Article
Medicine, General & Internal
Bartosz Bugaj, Joanna Wielinska, Katarzyna Bogunia-Kubik, Jerzy Swierkot
Summary: This study identified new biomarkers associated with the clinical presentation and treatment response in axSpA patients. SNPs can be used to identify high-risk patients and initiate early treatment.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Medicine, General & Internal
Christopher Ritchlin, Iannis E. Adamopoulos
Summary: Axial spondyloarthritis (axSpA) is an inflammatory disease of the axial skeleton associated with significant pain and disability. The discovery of the IL-23/IL-17 pathway led to the development of highly effective antibodies directed toward IL-17A for the treatment of axSpA. New agents with dual inhibition of IL-17A and F isoforms, along with oral small molecule agents targeting the Jak-STAT pathway, have also shown efficacy in treating axSpA.
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Immunology
Miladi Saoussen, Makhlouf Yasmine, Nacef Lilia, Fazaa Alia, Bousaa Hiba, Ben Abdelghani Kawther, Laatar Ahmed
Summary: The use of biologics has revolutionized the treatment of axial spondyloarthritis, with gradual tapering strategies showing success in maintaining sustained remission. However, further research is needed to explore the specific implications of each subset and establish more standardized tapering strategies.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Review
Rheumatology
Abhijeet Danve, Atul Deodhar
Summary: This review summarizes the progress in the pharmacological management of axial spondyloarthritis (axSpA), including newly approved biologic DMARDs. With advances in the understanding of the immunopathogenesis of this disease, new therapies have become available, which can substantially improve symptoms, signs and quality of life.
NATURE REVIEWS RHEUMATOLOGY
(2022)
Article
Rheumatology
Esther Beckers, Annelies Boonen, Casper Webers, Peter Ten Klooster, Harald Vonkeman, Monique Efde, Astrid van Tubergen
Summary: The study found that internationally agreed treat-to-target recommendations were applied to a limited extent in clinical practice for patients with axial spondyloarthritis. Available disease activity scores did not seem to be utilized for determining the frequency of re-evaluation or treatment adaptation.
Article
Rheumatology
Sonam Kiwalkar, Richard Howard, Dongseok Choi, Atul Deodhar
Summary: This study aims to understand the diagnostic journey and barriers for US patients with nonradiographic axial spondyloarthritis (nr-axSpA). Interviews and surveys revealed that delayed diagnosis of nr-axSpA is common, with women and individuals in rural areas being more likely to experience delays. Impediments to timely diagnosis include chronic pain, episodic symptoms, other symptoms requiring medical consultation, and lack of knowledge about nr-axSpA among healthcare providers. Targeted education and research are needed to improve timely diagnosis.
CLINICAL RHEUMATOLOGY
(2023)
Letter
Rheumatology
Anna Molto, Desiree van der Heijde, Filip E. van den Bosch, Maxime Dougados
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Augusta Ortolan, Sofia Ramiro, Roberta Ramonda, Desiree van der Heijde
Summary: The altASDAS index is a valid tool for assessing disease activity in axial SpA patients when patient global assessment is unavailable. It has been shown to be both truthful and discriminative in an external cohort, demonstrating its usefulness in clinical practice.
Review
Rheumatology
Dafne Capelusnik, Diego Benavent, Desiree van der Heijde, Robert Landewe, Denis Poddubnyy, Astrid van Tubergen, Louise Falzon, Victoria Navarro-Compan, Sofia Ramiro
Summary: This study conducted a systematic literature review to summarize the relationship between early treatment and treatment clinical response in patients with SpA. It found that early treatment was associated with better outcomes in patients with non-radiographic axSpA and symptom duration of less than 5 years, but no differences in response to treatment were found in radiographic axSpA or in patients with longer symptom duration.
Article
Rheumatology
Casper Webers, Uta Kiltz, Juergen Braun, Desiree van der Heijde, Annelies Boonen
Summary: Treating active SpA improves depressive symptoms, especially with TNF inhibitors (TNFis) which have a stronger effect mainly due to their impact on disease activity.
Article
Rheumatology
Desiree van der Heijde, Atul Deodhar, Xenofon Baraliakos, Matthew A. Brown, Hiroaki Dobashi, Maxime Dougados, Dirk Elewaut, Alicia M. Ellis, Carmen Fleurinck, Karl Gaffney, Lianne S. Gensler, Nigil Haroon, Marina Magrey, Walter P. Maksymowych, Alexander Marten, Ute Massow, Marga Oortgiesen, Denis Poddubnyy, Martin Rudwaleit, Julie Shepherd-Smith, Tetsuya Tomita, Filip van den Bosch, Thomas Vaux, Huji Xu
Summary: The BE MOBILE 1 and BE MOBILE 2 trials demonstrated that bimekizumab, a dual IL-17A and IL-17F inhibitor, improved efficacy outcomes in patients with axial spondyloarthritis (axSpA) and was well tolerated. These findings support the use of bimekizumab as a potential treatment option for axSpA.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Rheumatology
Andreas Kerschbaumer, Alexandre Sepriano, Sytske Anne Bergstra, Josef S. Smolen, Desiree van der Heijde, Roberto Caporali, Christopher John Edwards, Patrick Verschueren, Savia de Souza, Janet E. Pope, Tsutomu Takeuchi, Kimme L. Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja A. Stamm, Jan W. Schoones, Robert B. M. Landewe
Summary: This study aimed to update the evidence on the efficacy of DMARDs and provide information for the 2022 update of EULAR recommendations for RA management. A systematic literature review was conducted to investigate the efficacy of cs, b, biosimilar, and tsDMARDs in RA patients. The results showed that csDMARDs combined with short-term glucocorticoids in early RA were as effective as bDMARD+MTX combination therapy. JAK inhibitors were effective in different patient populations. Tapering of DMARDs was feasible for some patients who could maintain low disease activity or achieve remission.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Rheumatology
Alexandre Sepriano, Andreas Kerschbaumer, Sytske Anne Bergstra, Josef S. Smolen, Desiree van der Heijde, Roberto Caporali, Christopher J. Edwards, Patrick Verschueren, Savia de Souza, Janet Pope, Tsutomu Takeuchi, Kimme Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja Stamm, Jan W. Schoones, Robert B. M. Landewe
Summary: This study conducted a systematic literature review (SLR) to evaluate the safety of synthetic and biological disease-modifying antirheumatic drugs (DMARDs) for the management of rheumatoid arthritis (RA). The results indicated that bDMARDs were associated with an increased risk of serious infections compared to csDMARDs, while JAK inhibitors (JAKi) showed higher risk of herpes zoster infections. The risks of malignancies, major adverse cardiovascular events (MACE), and venous thromboembolism (VTE) were similar among different treatments.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Rheumatology
Sytske Anne Bergstra, Alexandre Sepriano, Andreas Kerschbaumer, Desiree van der Heijde, Roberto Caporali, Christopher John Edwards, Patrick Verschueren, Savia de Souza, Janet E. Pope, Tsutomu Takeuchi, Kimme L. Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja A. Stamm, Jan W. Schoones, Josef S. Smolen, Robert B. M. Landewe
Summary: This systematic literature review examines the efficacy, duration of use, and safety of glucocorticoids (GCs) in the management of rheumatoid arthritis (RA). The study confirms the effectiveness of GCs in treating RA, with most patients able to stop GCs within 12-24 months. However, the use of GCs also carries well-known safety risks, including osteoporotic fractures, serious infections, diabetes, and mortality.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Sofia Ramiro, Robert Landewe, Desiree van der Heijde, Alexandre Sepriano, Oliver FitzGerald, Mikkel Ostergaard, Joanne Homik, Ori Elkayam, J. Carter Thorne, Maggie J. Larche, Gianfranco Ferraccioli, Marina Backhaus, Gilles Boire, Bernard Combe, Thierry Schaeverbeke, Alain Saraux, Maxime Dougados, Maurizio Rossini, Marcello Govoni, Luigi Sinigaglia, Alain G. Cantagrel, Cornelia F. Allaart, Cheryl Barnabe, Clifton O. Bingham III, Dirkjan van Schaardenburg, Hilde B. Hammer, Rana Dadashova, Edna Hutchings, Joel Paschke, Walter P. Maksymowych
Summary: The study investigates whether meticulously following a treat-to-target (T2T) strategy in daily clinical practice leads to less radiographic progression in patients with active rheumatoid arthritis (RA). The findings show that a more stringent application of T2T does not result in less radiographic progression compared to a somewhat lenient attitude towards T2T.
Letter
Rheumatology
Sofia Ramiro, Elena Nikiphorou, Alexandre Sepriano, Augusta Ortolan, Casper Webers, Xenofon Baraliakos, Robert B. M. Landewe, Desiree van der Heijde
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Victoria Navarro-Compan, Diego Benavent, Dafne Capelusnik, Desiree van der Heijde, Robert B. M. Landewe, Denis Poddubnyy, Astrid van Tubergen, Xenofon Baraliakos, Filip E. van den Bosch, Floris A. van Gaalen, Lianne Gensler, Clementina Lopez-Medina, Helena Marzo-Ortega, Anna Molto, Rodolfo Perez-Alamino, Martin Rudwaleit, Marleen van de Sande, Raj Sengupta, Ulrich Weber, Sofia Ramiro
Summary: This study developed a consensual definition for 'early axial spondyloarthritis-axSpA' and 'early peripheral spondyloarthritis-pSpA' through a systematic literature review and Delphi survey. The results indicated that early axSpA should be based on symptom duration only, without considering the presence of radiographic damage.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Correction
Rheumatology
Atul Deodhar, Denis Poddubnyy, Proton Rahman, Jeorg Ermann, Tetsuya Tomita, Rebeca Bolce, Soyi Liu Leage, Andris Kronbergs, Caroline Johnson, Joana Araujo, Ann Leung, Desiree van der Heijde
JOURNAL OF RHEUMATOLOGY
(2023)
Article
Rheumatology
Rosalinde Stal, Sofia Ramiro, Xenofon Baraliakos, Juergen Braun, Monique Reijnierse, Rosaline van den Berg, Desiree van der Heijde, Floris A. van Gaalen
Summary: The objective of this study was to assess the construct validity of the CT Syndesmophyte Score (CTSS) for measuring structural spinal damage in patients with radiographic axial spondyloarthritis. The study compared the scores of CTSS and modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) in detecting syndesmophytes and their correlation with spinal mobility. The results demonstrated good agreement between CTSS and mSASSS in detecting syndesmophytes, and higher correlation of CTSS with spinal mobility measures.
Article
Rheumatology
Xenofon Baraliakos, Atul Deodhar, Desiree van der Heijde, Marina Magrey, Walter P. Maksymowych, Tetsuya Tomita, Huji Xu, Ute Massow, Carmen Fleurinck, Alicia M. Ellis, Thomas Vaux, Julie Shepherd-Smith, Alexander Marten, Lianne S. Gensler
Summary: Bimekizumab (BKZ), a monoclonal antibody that inhibits IL-17F and IL-17A, demonstrated sustained efficacy in patients with axial spondyloarthritis (axSpA) at Week 52. The dual inhibition of IL-17A and IL-17F resulted in significant improvements compared to placebo and the safety profile was consistent with previous findings.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Letter
Rheumatology
Valeriia Melokhina, Nina Paulshus Sundlisaeter, Joseph Sexton, Ulf Sundin, Anna-Birgitte Aga, Kaja E. Kjorholt, Lena Bugge Nordberg, Desiree van der Heijde, Espen Haavardsholm, Siri Lillegraven
ANNALS OF THE RHEUMATIC DISEASES
(2023)
